

COMPLETION OF CAPITAL CONSOLIDATION

Melbourne, Australia – 7 July 2026: Adherium Limited (“Adherium” or “the Company”) (ASX:ADR), a global leader in digital respiratory management and developer of the FDA-cleared Hailie® Smartinhale® platform is pleased to advise that following shareholder approval at the Extraordinary General Meeting held on 19 June 2026, the consolidation of issued capital of the Company on the basis of:

- (a) every hundred (100) Shares in the Company being consolidated into one (1) Share in the Company; and
- (b) all Options and Share Appreciation Rights (SAR's) on issue being consolidated in accordance with ASX Listing Rule 7.22.1,

is now complete.

The post consolidation securities on issue are as follows:

Quoted Securities	Number
ADR – ORDINARY FULLY PAID	54,887,674
Unquoted Securities	Number
ADRAA - OPTION EXPIRING 22-JAN-2029 EX \$1.00	539,088
ADRAB - OPTION EXPIRING 28-FEB-2028 EX \$2.00	3,072,042
ADRAC - OPTION EXPIRING 09-DEC-2027 EX \$0.41	20,000
ADRAD - OPTION EXPIRING VARIOUS DATES EX VARIOUS PRICES	105,660
ADRAE - OPTION EXPIRING 19-JUN-2027 EX \$0.80	4,000
ADRAF - OPTION EXPIRING 01-APR-2027 EX \$1.00	5,250
ADRAG - OPTION EXPIRING 15-MAR-2027 EX \$1.00	97,563
ADRAH - OPTION EXPIRING 29-JUN-2027 EX \$0.80	17,500
ADRAI - OPTION EXPIRING 13-JUL-2027 EX \$0.80	8,000
ADRAP - STOCK APPRECIATION RIGHTS	246,604
ADRAW - OPTION EXPIRING 31-JUL-2026 EX \$0.50	3,250,634
ADRAX - OPTION EXPIRING 15-NOV-2026 EX \$0.50	6,581,153
ADRAY - OPTION EXPIRING 05-DEC-2028 EX \$2.00	500,000

In accordance with the terms of the Resolution 6 - Approval of Share Consolidation, approved at the Extraordinary General Meeting, where the consolidation resulted in a fraction of a security being held, the Company rounded that fraction up to the nearest whole security, as applicable.

New holding statements have been dispatched to shareholders on a post consolidation basis.

Trading on a normal T+2 settlement basis will commence on Wednesday, 8 July 2026.



ASX Release

- ENDS -

This ASX announcement was approved and authorised for release by the Board of Adherium.

Investor Enquiries

Adherium Limited

investors@adherium.com

Media Enquiries:

Haley Chartres

HACK Director

haley@hck.digital

About Adherium (ASX: ADR):

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management. The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease. Learn more at [adherium.com](https://www.adherium.com)